Our previous study had compared the clinical and pathological characteristics of iMN and aMN patients, discovered the mainly clinical manifestation of these two groups was nephrotic syndrome (61.5 % in iMN group vs. 58.4 % in aMN group), but there were more patients accompanied with nephritis syndrome in aMN group than iMN group (17.1 % vs. 6.1 %, P < 0.001), there was slight difference on laboratory examination between the two groups, serum anti-phospholipase A2 receptor (PLA2R) antibody could not distinguish aMN from iMN[7]. This evidence concerns the gene PLA2R1 and adrenomyeloneuropathy.